Legal & General Group
AMRI

Legal & General Group’s Albany Molecular Research Inc AMRI Stock Holding History

Legal & General Group’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-41,310
Closed -$897K – 3358
2017
Q2 		$897K Buy
41,310
+4,234
+11% +$76.8K ﹤0.01% 1866
2017
Q1 		$520K Sell
37,076
-80
-0.2% -$1.31K ﹤0.01% 2022
2016
Q4 		$697K Buy
37,156
+17,832
+92% +$303K ﹤0.01% 1878
2016
Q3 		$317K Buy
19,324
+15,100
+357% +$224K ﹤0.01% 1904
2016
Q2 		$56K Hold
4,224
– – ﹤0.01% 2428
2016
Q1 		$65K Sell
4,224
-32
-0.8% -$502 ﹤0.01% 2303
2015
Q4 		$85K Hold
4,256
– – ﹤0.01% 2174
2015
Q3 		$74K Hold
4,256
– – ﹤0.01% 2218
2015
Q2 		$85K Hold
4,256
– – ﹤0.01% 2243
2015
Q1 		$74K Hold
4,256
– – ﹤0.01% 2247
2014
Q4 		$68K Sell
4,256
-325
-7% -$5.96K ﹤0.01% 2261
2014
Q3 		$101K Buy
+4,581
New +$93.8K ﹤0.01% 1885

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Legal & General Group's AMRI Position: Q3 2017 in Review

Legal & General Group sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 41,310 shares — an estimated $897K sold.

Legal & General Group first reported a position in AMRI in Q3 2014 and held it in 12 quarters. The position peaked at $897K in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Legal & General Group reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Legal & General Group sold 41,310 Albany Molecular Research Inc shares in Q3 2017, an estimated $897K.
  • Legal & General Group first reported a position in Albany Molecular Research Inc in Q3 2014 and held it in 12 quarters.
  • Legal & General Group's Albany Molecular Research Inc position peaked at $897K in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Legal & General Group's 13F filing for Q3 2017, filed 9 Nov 2017.